A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis
is 10-100 times higher than the normal population. This is due in part to high levels of
inflammation and vascular calcification found in these patients. Phosphate binders,
particularly non-calcium based phosphate binders, may decrease cardiovascular risk by
decreasing inflammation and vascular calcification. Ferric citrate a non-calcium based
phosphate binder with approximately 210 mg of ferric iron has recently been approved for
patients on hemodialysis. The effect of this phosphate binder on inflammation and lipid
levels is unknown but investigators hypothesize that ferric citrate has the potential to
improve inflammation and lipid levels in patients on hemodialysis by decreasing intravenous
iron requirements and by improving lipid metabolism.